{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:12:48Z","timestamp":1783930368442,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019864","name":"Universidade Nove De Julho","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019864","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Benign prostatic hyperplasia (BPH) is a highly prevalent condition among aging men and a major cause of lower urinary tract symptoms (LUTS). Although \u03b11-adrenoceptor blockers and 5-alpha-reductase inhibitors remain the cornerstone of treatment, their long-term use is frequently limited by adverse effects and suboptimal symptom control. Growing experimental and clinical evidence suggests that chronic prostatic inflammation plays a central role in BPH progression, raising interest in anti-inflammatory compounds such as curcumin. However, the clinical effectiveness of curcumin in BPH remains poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of randomized and nonrandomized comparative studies evaluating curcumin versus placebo in men with BPH receiving \u03b1-blockers and\/or 5-alpha-reductase inhibitors. Searches were performed in PubMed, Embase, and Cochrane CENTRAL. The primary outcome was change in International Prostate Symptom Score (IPSS). Secondary outcomes included prostate-specific antigen (PSA), prostate volume (PV), post-void residual volume (PVR), and maximum urinary flow rate (Q-max). Pooled analyses were performed using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six studies involving 697 patients met the inclusion criteria. Compared with placebo, curcumin was associated with a significant improvement in IPSS (MD\u2009\u2212\u20094.11;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0009), accompanied by reductions in PSA (MD\u2009\u2212\u20090.52\u00a0ng\/mL), PV (MD\u2009\u2212\u20093.78\u00a0mL), and PVR (MD -2.38\u00a0mL), as well as an increase in Q-max (MD 2.09\u00a0mL\/s). Subgroup analyses suggested greater symptomatic benefit among patients receiving \u03b1-blockers alone compared with those on combined \u03b1-blocker and 5-alpha-reductase inhibitor therapy. Substantial heterogeneity was observed across outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Curcumin supplementation was associated with significant improvement in LUTS and functional parameters in men with BPH. Although these findings support a potential adjunctive role for curcumin, the available evidence is limited by heterogeneity and study design variability. Well-designed, large-scale randomized trials are warranted to define its clinical utility, optimal formulation, and long-term effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04093-9","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:51:43Z","timestamp":1780635103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Curcumin versus placebo in benign prostatic hyperplasia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Diogo Souto","family":"Santana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno Cordeiro","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Baldissera","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Melchior Maia","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Guilherme Serr\u00e3o","family":"Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Camargo","family":"Passerotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Gon\u00e7alves","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Afonso","family":"da Silva Sardenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Arnaldo Shiomi","family":"da Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"4","key":"4093_CR1","first-page":"135","volume":"45","author":"F Di Silverio","year":"1993","unstructured":"Di Silverio F, D\u2019Eramo G, Flammia GP, Caponera M, Frascaro E, Buscarini M, Mariani M, Sciarra A (1993) Pathology of BPH. Minerva Urol Nefrol 45(4):135\u2013142","journal-title":"Minerva Urol Nefrol"},{"issue":"3","key":"4093_CR2","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132(3):474\u2013479. https:\/\/doi.org\/10.1016\/s0022-5347(17)49698-4","journal-title":"J Urol"},{"issue":"5","key":"4093_CR3","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.juro.2016.06.090","volume":"196","author":"JC Nickel","year":"2016","unstructured":"Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM (2016) Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention. J Urol 196(5):1493\u20131498. https:\/\/doi.org\/10.1016\/j.juro.2016.06.090","journal-title":"J Urol"},{"issue":"25","key":"4093_CR4","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387\u20132398. https:\/\/doi.org\/10.1056\/NEJMoa030656","journal-title":"N Engl J Med"},{"key":"4093_CR5","unstructured":"Lepor H (2007) Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 9(4):181\u201390"},{"key":"4093_CR6","doi-asserted-by":"publisher","unstructured":"Cicero AFG, Allkanjari O, Busetto GM, Cai T, Largan\u00e0 G, Magri V, Perletti G, Robustelli Della Cuna FS, Russo GI, Stamatiou K, Trinchieri A, Vitalone A (2019) Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl 91(3). https:\/\/doi.org\/10.4081\/aiua.2019.3.139","DOI":"10.4081\/aiua.2019.3.139"},{"issue":"11","key":"4093_CR7","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00345-020-03106-1","volume":"38","author":"C De Nunzio","year":"2020","unstructured":"De Nunzio C, Salonia A, Gacci M, Ficarra V (2020) Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol 38(11):2771\u20132779. https:\/\/doi.org\/10.1007\/s00345-020-03106-1","journal-title":"World J Urol"},{"issue":"1","key":"4093_CR8","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1080\/13880209.2021.1953539","volume":"59","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wang Z, Gan Y, Chen X, Zhang B, Chen Z, Liu P, Li B, Ru F, He Y (2021) Curcumin attenuates prostatic hyperplasia caused by inflammation viaup-regulation of bone morphogenetic protein and activin membrane-bound inhibitor. Pharm Biol 59(1):1026\u20131035. https:\/\/doi.org\/10.1080\/13880209.2021.1953539","journal-title":"Pharm Biol"},{"issue":"1","key":"4093_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","volume":"15","author":"SC Gupta","year":"2013","unstructured":"Gupta SC, Patchva S, Aggarwal BB (2013) Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15(1):195\u2013218. https:\/\/doi.org\/10.1208\/s12248-012-9432-8","journal-title":"AAPS J"},{"key":"4093_CR10","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Paris April 2024. ISBN 978\u201394\u201392671\u201323\u20133"},{"issue":"1","key":"4093_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, Wilt TJ (2024) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol 211(1):11\u201319. https:\/\/doi.org\/10.1097\/JU.0000000000003698","journal-title":"J Urol"},{"issue":"3","key":"4093_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff J M, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 18(3):e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583","journal-title":"PLoS Med"},{"key":"4093_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4093_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hr\u00f3bjartsson A, Kirkham J, J\u00fcni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Sch\u00fcnemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"4093_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-3-319-93791-5_2","volume":"1082","author":"BKC Chan","year":"2018","unstructured":"Chan BKC (2018) Data analysis using R programming. Adv Exp Med Biol 1082:47\u2013122. https:\/\/doi.org\/10.1007\/978-3-319-93791-5_2","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"4093_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1070-0","volume":"8","author":"L Schmidt","year":"2019","unstructured":"Schmidt L, Shokraneh F, Steinhausen K, Adams CE (2019) Introducing RAPTOR: RevMan parsing tool for reviewers. Syst Rev 8(1):151. https:\/\/doi.org\/10.1186\/s13643-019-1070-0","journal-title":"Syst Rev"},{"issue":"1 Suppl 4","key":"4093_CR17","first-page":"17","volume":"54","author":"A Ledda","year":"2012","unstructured":"Ledda A, Belcaro G, Dugall M, Luzzi R, Scoccianti M, Togni S, Appendino G, Ciammaichella G (2012) Meriva\u00ae, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: a pilot, product evaluation registry study. Panminerva Med 54(1 Suppl 4):17\u201322","journal-title":"Panminerva Med"},{"issue":"10-12","key":"4093_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1159\/000534148","volume":"107","author":"F Crocerossa","year":"2023","unstructured":"Crocerossa F, Cantiello F, Bagal\u00e1 L, Sicoli F, Carbonara U, Manfredi C, Falagario U, Veccia A, Pandolfo SD, Napolitano L, Ferro M, Di Dio M, Mondaini N, Damiano R (2023) Clinical effects of oral supplementation of Gamma-Cyclodextrin Curcumin Complex in male patients with moderate-to-severe Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms. Urol Int 107(10\u201312):924\u2013934. https:\/\/doi.org\/10.1159\/000534148","journal-title":"Urol Int"},{"issue":"9","key":"4093_CR19","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00345-023-04512-x","volume":"41","author":"AA Karami","year":"2023","unstructured":"Karami AA, Zameni H, Salehi M, Mirhashemi SM (2023) The nano-micellar Curcumin improves International Prostate Symptoms Score (IPSS) in patients with Benign Prostatic Hyperplasia: a randomized clinical trial. World J Urol 41(9):2465\u20132471. https:\/\/doi.org\/10.1007\/s00345-023-04512-x","journal-title":"World J Urol"},{"issue":"8","key":"4093_CR20","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.21037\/tau-21-567","volume":"10","author":"J Qiao","year":"2021","unstructured":"Qiao J, Gan Y, Gong Y, Song Q, Zhang B, Li B, Ru F, Li Y, He Y (2021) Combination therapy with Curcumin plus Tamsulosin and Finasteride in the treatment of men with Benign Prostatic Hyperplasia: a single center, randomized control study. Transl Androl Urol 10(8):3432\u20133439. https:\/\/doi.org\/10.21037\/tau-21-567","journal-title":"Transl Androl Urol"},{"issue":"1","key":"4093_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.21886\/2308-6424-2022-10-1-84-95","volume":"10","author":"SV Shkodkin","year":"2022","unstructured":"Shkodkin SV, Pokrovskiy MV, Krasnyak SS, Polishchuk AV, Chirkov SV, Churikova OV, Kravtsova NA (2022) Combination therapy for benign prostate hyperplasia-related urinary symptoms. Vestn Urol 10(1):84\u201395. https:\/\/doi.org\/10.21886\/2308-6424-2022-10-1-84-95. ((In Russ.))","journal-title":"Vestn Urol"},{"issue":"4","key":"4093_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041689","volume":"12","author":"G Milanese","year":"2023","unstructured":"Milanese G, Agostini E, De Angelis MV, Pretore E, Galosi AB, Castellani D (2023) Efficacy of 1-year Cavacurmin\u00ae therapy in reducing prostate growth in men suffering from Lower Urinary Tract Symptoms. J Clin Med 12(4):1689. https:\/\/doi.org\/10.3390\/jcm12041689","journal-title":"J Clin Med"},{"issue":"1","key":"4093_CR23","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1080\/13880209.2021.1953539","volume":"59","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wang Z, Gan Y, Chen X, Zhang B, Chen Z, Liu P, Li B, Ru F, He Y (2021) Curcumin attenuates prostatic hyperplasia caused by inflammation via up-regulation of Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor. Pharm Biol 59(1):1026\u20131035. https:\/\/doi.org\/10.1080\/13880209.2021.1953539","journal-title":"Pharm Biol"},{"issue":"11","key":"4093_CR24","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.3109\/10428194.2014.889824","volume":"55","author":"L Das","year":"2014","unstructured":"Das L, Vinayak M (2014) Long-term effect of Curcumin down-regulates expression of Tumor Necrosis Factor-\u03b1 and Interleukin-6 via modulation of E26 transformation-specific protein and Nuclear Factor-\u03baB transcription factors in livers of lymphoma bearing mice. Leuk Lymphoma 55(11):2627\u20132636. https:\/\/doi.org\/10.3109\/10428194.2014.889824","journal-title":"Leuk Lymphoma"},{"key":"4093_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113703","volume":"279","author":"S Wang","year":"2021","unstructured":"Wang S, Li Y, Li W, Zhang K, Yuan Z, Cai Y, Xu K, Zhou J, Du Z (2021) Curcuma oil ameliorates benign prostatic hyperplasia through suppression of the Nuclear Factor-kappa B signaling pathway in rats. J Ethnopharmacol 279:113703. https:\/\/doi.org\/10.1016\/j.jep.2020.113703","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"4093_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0895-3988(09)60019-2","volume":"22","author":"SL Wang","year":"2009","unstructured":"Wang SL, Li Y, Wen Y, Chen YF, Na LX, Li ST, Sun CH (2009) Curcumin, a potential inhibitor of up-regulation of TNF-alpha and IL-6 induced by Palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway. Biomed Environ Sci 22(1):32\u201339. https:\/\/doi.org\/10.1016\/S0895-3988(09)60019-2","journal-title":"Biomed Environ Sci"},{"issue":"3","key":"4093_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.5534\/wjmh.240071","volume":"43","author":"GH Lee","year":"2025","unstructured":"Lee GH, Shin YS, Kim JH, Shim DH, Lee HY, Zhao L, Rashid MM, Cho HE, Lee JJ, Kim MK, Kim DS, Park HJ, Chae HJ (2025) The combination of Curcumae Radix and Syzygium Aromaticum extracts mitigates Benign Prostatic Hyperplasia through anti-proliferative and anti-inflammatory effects. World J Mens Health 43(3):603\u2013615. https:\/\/doi.org\/10.5534\/wjmh.240071","journal-title":"World J Mens Health"},{"issue":"12","key":"4093_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-014-0463-9","volume":"15","author":"V Ficarra","year":"2014","unstructured":"Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, Mirone V, Scaglione F (2014) The role of inflammation in Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep 15(12):463. https:\/\/doi.org\/10.1007\/s11934-014-0463-9","journal-title":"Curr Urol Rep"},{"issue":"1","key":"4093_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.biocel.2008.06.010","volume":"41","author":"BB Aggarwal","year":"2009","unstructured":"Aggarwal BB, Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41(1):40\u201359. https:\/\/doi.org\/10.1016\/j.biocel.2008.06.010","journal-title":"Int J Biochem Cell Biol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04093-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04093-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04093-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:21Z","timestamp":1783929441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04093-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4093"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04093-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics, consent to participate, and consent to publish declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}